Clinical trials: Hepatobiliary Disorders
HBV, NASH - Nonalcoholic Steatohepatitis
Mechanism of DCs Dysfunction in Chronic HBV Infection
This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their…
- Trial name
- HepatoDC (NCT03753308)
- Testing
- Blood Sampling, Liver biopsy
- Where
- France
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Nonalcoholic Fatty Liver, Metabolic Syndrome
Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet medical needs. Aim of this study is to investigate the blood levels of three hormonal systems related to obesity, insulin resistance…
- Trial name
- NAFLD (NCT03986684)
- Where
- Greece
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hippocration General Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
The goal of this observational study is to establish a multi-center registry to better understand Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using health screening data from Korean hospitals.
- Trial name
- K-MASLD (NCT06843421)
- Where
- 5 sites in South Korea
- Volunteers
- 6,000 people
- Sponsor
- Korea University
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
The purpose of this study is to evaluate whether exenatide is superior to insulin glargine (after 24 weeks) in reducing liver fat content (by MRS) in patients with newly diagnosed type 2 diabetes mellitus and concomitant…
- Trial name
- NCT02303730
- Testing
- Exenatide, insulin glargine
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Non-alcoholic Steatohepatitis
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
This is a double-blind, placebo-controlled study in adults with non-alcoholic steatohepatitis and Type 2 Diabetes Mellitis on stable dose of metformin monotherapy.
- Trial name
- NCT03969719
- Testing
- PF-06835919
- Where
- 106 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Pfizer
Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver
Effect of a GnRH Analog on Hepatic Steatosis
Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis
- Trial name
- EndomMASLD (NCT06523530)
- Testing
- Goserelin Acetate 3.6 mg inj, implant
- Where
- 2 sites in Greece
- Volunteers
- 62 people
- Sponsor
- Aristotle University Of Thessaloniki
Liver Transplant Disorder
Developing Prediction Models for Allograft Failure After Liver Transplantation
Prompt identification of allograft failure (AF) is highly desirable to address patients to liver retransplantation, in order to maximize results and preserve patients safety.
- Trial name
- IMPROVEMENT (NCT05289609)
- Testing
- Liver Transplantation
- Where
- 18 sites in United States, Argentina and 9 more
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Alcohol Liver Disease
Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.
ALD is the most common cause of liver cirrhosis in western world. In patients with ALD persistent alcohol intake is associated with increased mortality while cessation of alcohol consumption improve survival.
- Trial name
- NCT06175507
- Testing
- Naltrexon, Baclofen
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Autoimmune Liver Disease, Autoimmune Hepatitis
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- NCT03178630
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
NAFLD
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Objectives To evaluate the efficacy, safety, and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05768334
- Testing
- Lubiprostone 24Mcg Oral twice daily
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Helwan University
NASH - Nonalcoholic Steatohepatitis
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
- Trial name
- NCT03912532
- Testing
- NGM282
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
This is a multicenter, prospective, randomized controlled investigator-initiated trial (IIT) aimed at evaluating the efficacy and safety of switching to mazdutide therapy in patients with type 2 diabetes mellitus (T2DM) and…
- Trial name
- NCT07713992
- Testing
- Mazdutide(Dual GLP-1R/GCGR Agonist), Semaglutide (1 Mg Dose)
- Volunteers
- 72 people
- Sponsor
- Tianjin Medical University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
The Liver Health Study for Patients with NAFLD
The study will investigate whether the level of fat stored in the liver is related to the liver's ability to burn fat.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NCT03151798
- Testing
- Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Missouri-Columbia
Fatty Liver Disease, Fibrosis, Liver
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
This study will evaluate the effect of probiotics, a beneficial intestinal bacteria supplement, if it will cause improvement of the non-alcoholic fatty liver disease (NAFLD) and or non-alcoholic steatohepatitis (NASH- an…
- Conditions
- Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
- Trial name
- PRONE (NCT04175392)
- Testing
- Align Probiotic Supplement Capsule
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corewell Health East
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
This is a 3-month, single-center, prospective, randomized, parallel-controlled, open-label trial investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes…
- Trial name
- MDEITM (NCT07778719)
- Testing
- Metformin + Dapagliflozin, Metformin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- The 95th Hospital of Putian，Putian, Fujian, China
Non-alcoholic Fatty Liver Disease
Quantitative Detection Efficiency of UDFF for Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting more than 25 % of the population globally.
- Trial name
- UDFF (NCT05802199)
- Testing
- Hepatic fat fraction and hepatic fibrosis
- Where
- 14 sites in China, Switzerland
- Volunteers
- 300 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Serum Irisin Levels in Obese Children
Serum Irisin Levels in Obese Children
Irisin is a myokine induced by exercise, that converts white fat tissue to brown fat tissue, thereby increases thermogenesis and energy expenditure.
- Trial name
- NCT04524936
- Testing
- blood sample
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eskisehir Osmangazi University
Nonalcoholic Steatohepatitis
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic…
- Trial name
- NCT02442687
- Testing
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily
- Where
- 8 sites in United States
- Volunteers
- 65 people
- Sponsor
- Manal Abdelmalek
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.